Lupus-Associated Pulmonary Arterial Hypertension
Early recognition of severe PAH as a cause of dyspnea and hemodynamic instability in rheumatologic patients is essential for timely intervention. Immunosuppressive therapy should be considered an integral component of PAH-specific treatment, as it may significantly improve prognosis in autoimmune-related PAH.
Authors
- Eduardo Dourado (ORCID: https://orcid.org/0000-0003-2186-2833)
- Fausto José Pinto (ORCID: https://orcid.org/0000-0002-8034-4529)
- A Abrantes (ORCID: https://orcid.org/0000-0002-1295-9679)
- Tatiana Guimarães (ORCID: https://orcid.org/0000-0001-7054-0465)
- Tomás Fontes (ORCID: https://orcid.org/0000-0002-5629-7961)
- Rui Plácido (ORCID: https://orcid.org/0000-0003-4164-5481)
- Catarina Gregório (ORCID: https://orcid.org/0009-0001-3039-1749)
- Daniel Inácio Cazeiro (ORCID: https://orcid.org/0009-0004-0277-7398)
Institutions
- Hospital do Divino Espírito Santo (PT)
- Hospital de Santa Maria (PT)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1016/j.jaccas.2025.104906
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundação para a Ciência e a Tecnologia